Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma - Scorecard - MDSpire

Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

  • By

  • Neil J. Shah

  • Yaa Ababio

  • Anthony Eccleston

  • Dharanija Rao

  • Scott P. Kelly

  • Jane Chang

  • Sarah Lucht

  • Caleb Paydar

  • Bryce A. Van Doren

  • Emily Bland

  • William John

  • Sarah Giegerich

  • JaLyna Laney

  • Bruce Feinberg

  • Kevin K. Zarrabi

  • May 21, 2026

  • 0 min

Share

Clinical Scorecard: Management of Adverse Events in Advanced Renal Cell Carcinoma Patients Treated with Axitinib and Pembrolizumab

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care SettingMultisite oncology practices in the US

Key Highlights

  • Add statistics on treatment-related AEs leading to dose reductions and interruptions.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Implement specific monitoring protocols for common AEs associated with axitinib-pembrolizumab.

      Risks

        Patient & Prescribing Data

        Patients aged 18 and older with confirmed clear cell aRCC (stage IV) initiating first-line axitinib-pembrolizumab.

        Treatment-related AEs were the most common reasons for dose reductions and interruptions.

        Clinical Best Practices

        • Integrate recent clinical data on AE management strategies.

        Related Resources & Content

        Original Source(s)

        Axitinib-Pembrolizumab and Adverse Event Management in Patients With Advanced Renal Cell Carcinoma

        • by Neil J. Shah, Yaa Ababio, Anthony Eccleston, Dharanija Rao, Scott P. Kelly, Jane Chang, Sarah Lucht, Caleb Paydar, Bryce A. Van Doren, Emily Bland, William John, Sarah Giegerich, JaLyna Laney, Bruce Feinberg, Kevin K. Zarrabi

        • May 21, 2026

        Related Content

        Case Report: First description of an intracranial “NET” in ROHHAD syndrome; time to rename to the ROHHAD-NeCT syndrome?

        Ultra-high-sensitivity next-generation sequencing–based MRD predicts outcome in intensively treated older patients with acute myeloid leukemia: results from the ALFA-1200 cohort

        MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate